Petter Höglund group

One research focus in the group is to understand the molecular mechanisms responsible for immunological tolerance.

In particular, we study natural killer cells in the mouse using a combination of cellular immunology, biophysical imaging and mathematical modeling. The intracellular signals that control functional responses and development under various conditions are studied.

A second question is to ask how various components of the immune system impact on the outcome of erythrocyte and platelet transfusion in humans.

One aim is to understand how antibodies to HLA molecules makes patients refractory to platelet transfusions and another is to study natural killer cells in transfusion reactions. The aim is to develop means to avoid such reactions and to improve transfusion practices.

Keywords: immunology, natural killer cells, tolerance, platelet transfusions, HLA, intracellular signaling


Petter Höglund, MD PhD, Professor, Group Leader
Iyadh Douagi, PhD, FACS manager
Nadir Kadri, PhD, Research assistant
Stephan Meinke, Postdoc
Sridharan Ganesan, PhD student
Luu Thanh Thuy, PhD student

Selected publications

Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets.
Brodin P, Lakshmikanth T, Kärre K, Höglund P
J. Immunol. 2012 Mar;188(5):2218-26

A modified FCCS procedure applied to Ly49A-MHC class I cis-interaction studies in cell membranes.
Strömqvist J, Johansson S, Xu L, Ohsugi Y, Andersson K, Muto H, et al
Biophys. J. 2011 Sep;101(5):1257-69

Current perspectives of natural killer cell education by MHC class I molecules.
Höglund P, Brodin P
Nat. Rev. Immunol. 2010 Oct;10(10):724-34

NK cell education: not an on-off switch but a tunable rheostat.
Brodin P, Kärre K, Höglund P
Trends Immunol. 2009 Apr;30(4):143-9

The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells.
Brodin P, Lakshmikanth T, Johansson S, Kärre K, Höglund P
Blood 2009 Mar;113(11):2434-41

HematologyRegenerative Medicine